{
  "id": "5c58a74e86df2b917400000d",
  "type": "yesno",
  "question": "Is Baloxavir effective for influenza?",
  "ideal_answer": "Yes. Baloxavir is approved for influenza A or B virus infections.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30395523",
    "http://www.ncbi.nlm.nih.gov/pubmed/30316915",
    "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
    "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
    "http://www.ncbi.nlm.nih.gov/pubmed/30476172",
    "http://www.ncbi.nlm.nih.gov/pubmed/30396860",
    "http://www.ncbi.nlm.nih.gov/pubmed/30203386",
    "http://www.ncbi.nlm.nih.gov/pubmed/29941893"
  ],
  "snippets": [
    {
      "text": "Baloxavir marboxil (Xofluza\u2122; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Baloxavir acid (BXA), derived from the prodrug baloxavir marboxil (BXM), potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29941893",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29941893",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A single oral dose of baloxavir is usually well tolerated; it hastens alleviation of influenza symptoms and shortens the duration of viral shedding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Japan was the first country to approve baloxavir marboxil as a treatment for influenza.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}